Rainer Henning
Chief Executive Officer at Biomay AG
Rainer Henning active positions
Companies | Position | Start | End |
---|---|---|---|
Biomay AG
Biomay AG BiotechnologyHealth Technology Biomay AG researches and develops disease modifying allergy therapeutics. The firm discover and develop recombinant allergy vaccines with a superior efficacy and safety profile and these innovative vaccines are based on cutting edge science for immunotherapy and prophylaxis. It offers cGMP contract manufacturing services for the production of recombinant biologicals as active pharmaceutical ingredients. The company was founded in 1984 and is headquartered in Vienna, Austria. | Chief Executive Officer | - | - |
Career history of Rainer Henning
Former positions of Rainer Henning
Companies | Position | Start | End |
---|---|---|---|
FIBREX Medical, Inc.
FIBREX Medical, Inc. Miscellaneous Commercial ServicesCommercial Services FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company was founded to convert high impact scientific discovery into pharmaceutical products for important diseases. The company aims to become a leader in the development and commercialization of pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. While inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction. | President | - | 04/02/2013 |
Sanofi-Aventis U.S. LLC
Sanofi-Aventis U.S. LLC Pharmaceuticals: MajorHealth Technology Sanofi-Aventis U.S. LLC engages in the provision of pharmaceutical products. It discovers, develops, produces and markets innovative therapies. The firm extensive research and development efforts are focused on health care challenges in cardiology, oncology and internal medicine, as well as metabolic diseases, central nervous system disorders, ophthalmology and vaccines. The company is headquartered in Bridgewater, NJ. | Chief Tech/Sci/R&D Officer | - | - |
Statistics
International
Austria | 3 |
United States | 2 |
Operational
President | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Chief Executive Officer | 1 |
Sectoral
Health Technology | 3 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 3 |
---|---|
FIBREX Medical, Inc.
FIBREX Medical, Inc. Miscellaneous Commercial ServicesCommercial Services FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company was founded to convert high impact scientific discovery into pharmaceutical products for important diseases. The company aims to become a leader in the development and commercialization of pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. While inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction. | Commercial Services |
Sanofi-Aventis U.S. LLC
Sanofi-Aventis U.S. LLC Pharmaceuticals: MajorHealth Technology Sanofi-Aventis U.S. LLC engages in the provision of pharmaceutical products. It discovers, develops, produces and markets innovative therapies. The firm extensive research and development efforts are focused on health care challenges in cardiology, oncology and internal medicine, as well as metabolic diseases, central nervous system disorders, ophthalmology and vaccines. The company is headquartered in Bridgewater, NJ. | Health Technology |
Biomay AG
Biomay AG BiotechnologyHealth Technology Biomay AG researches and develops disease modifying allergy therapeutics. The firm discover and develop recombinant allergy vaccines with a superior efficacy and safety profile and these innovative vaccines are based on cutting edge science for immunotherapy and prophylaxis. It offers cGMP contract manufacturing services for the production of recombinant biologicals as active pharmaceutical ingredients. The company was founded in 1984 and is headquartered in Vienna, Austria. | Health Technology |
- Stock Market
- Insiders
- Rainer Henning
- Experience